Jeff Barrett named founding director of Centre for Therapeutic Target Validation with GSK and Wellcome

2 March 2015

Jeffrey Barrett has been appointed the founding director for the Centre for Therapeutic Target Validation, a public-private partnership between GlaxoSmithKline (LSE: GSK), the European Bioinformatics Institute and the Wellcome Trust Sanger Institute.

He has been involved in the CTTV since its inception last year, and will begin in the new role from May 1, 2015. The center uses genome-scale experiments and analysis to validate therapeutic targets and focus research into treatments including for cancer, inflammatory bowel disease and respiratory disease. It is committed to data-sharing with the scientific community.

Dr Barrett is currently a group leader at the Wellcome Trust Sanger Institute.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK